368 related articles for article (PubMed ID: 15573894)
1. [Treatment of hepatitis B].
Telegdy L
Orv Hetil; 2004 Nov; 145(45):2293-6. PubMed ID: 15573894
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B virus infection--natural history and clinical consequences.
Ganem D; Prince AM
N Engl J Med; 2004 Mar; 350(11):1118-29. PubMed ID: 15014185
[No Abstract] [Full Text] [Related]
3. [Chronic hepatitis B].
Thimme R; Spangenberg HC; Blum HE
Dtsch Med Wochenschr; 2008 Jan; 133(4):135-8. PubMed ID: 18197589
[No Abstract] [Full Text] [Related]
4. Pharmacology, clinical efficacy and safety of lamivudine in hepatitis B virus infection.
Kumar M; Sarin SK
Expert Rev Gastroenterol Hepatol; 2008 Aug; 2(4):465-95. PubMed ID: 19072396
[TBL] [Abstract][Full Text] [Related]
5. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
Leemans WF; Niesters HG; van der Eijk AA; Janssen HL; Schalm SW; de Man RA
Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):773-7. PubMed ID: 18617782
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus: old, new and future approaches to antiviral treatment.
Karayiannis P
J Antimicrob Chemother; 2003 Apr; 51(4):761-85. PubMed ID: 12654750
[TBL] [Abstract][Full Text] [Related]
7. Chronic hepatitis B: back to the future with HBsAg.
Moucari R; Lada O; Marcellin P
Expert Rev Anti Infect Ther; 2009 Aug; 7(6):633-6. PubMed ID: 19681689
[No Abstract] [Full Text] [Related]
8. Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan.
Suzuki Y; Kobayashi M; Ikeda K; Suzuki F; Arfase Y; Akuta N; Hosaka T; Saitoh S; Kobayashi M; Someya T; Matsuda M; Sato J; Watabiki S; Miyakawa Y; Kumada H
J Med Virol; 2005 May; 76(1):33-9. PubMed ID: 15779048
[TBL] [Abstract][Full Text] [Related]
9. Prophylaxis and treatment of recurrent viral hepatitis after liver transplantation.
Riediger C; Berberat PO; Sauer P; Gotthardt D; Weiss KH; Mehrabi A; Merle U; Stremmel W; Encke J
Nephrol Dial Transplant; 2007 Sep; 22 Suppl 8():viii37-viii46. PubMed ID: 17890261
[TBL] [Abstract][Full Text] [Related]
10. Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome.
Manolakopoulos S; Bethanis S; Elefsiniotis J; Karatapanis S; Triantos C; Sourvinos G; Touloumi G; Economou M; Vlachogiannakos J; Spandidos D; Avgerinos A; Tzourmakliotis D
Aliment Pharmacol Ther; 2006 Mar; 23(6):787-95. PubMed ID: 16556181
[TBL] [Abstract][Full Text] [Related]
11. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels.
Wong DK; Yuen MF; Ngai VW; Fung J; Lai CL
Antivir Ther; 2006; 11(7):909-16. PubMed ID: 17302253
[TBL] [Abstract][Full Text] [Related]
12. Fatal liver failure with the emergence of hepatitis B surface antigen variants with multiple stop mutations after discontinuation of lamivudine therapy.
Zhang JM; Wang XY; Huang YX; Yin YK; Guan S; Xu Y; Roggendorf M; Lu M
J Med Virol; 2006 Mar; 78(3):324-8. PubMed ID: 16419112
[TBL] [Abstract][Full Text] [Related]
13. [Post-transplant prophylaxis of the recurrence of lamivudine-resistant YMDD mutant hepatitis B virus in liver recipients].
Yang Y; Yang Y; Zhang J; Yi HM; Lu MQ; Cai CJ; Li X; Jiang N; Xu C; Li H; Wang GS; Yi SH; Zhang JF; Jiang H; Yang Q; Chen GH
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1810-2. PubMed ID: 18971179
[TBL] [Abstract][Full Text] [Related]
14. Chronic hepatitis B: a wider range of therapeutic options.
Prescrire Int; 2007 Aug; 16(90):157-62. PubMed ID: 17724844
[TBL] [Abstract][Full Text] [Related]
15. Preventing infection-associated cancer: from bench to hillside.
Goedert JJ
J Natl Cancer Inst; 2005 Feb; 97(4):245-6. PubMed ID: 15713953
[No Abstract] [Full Text] [Related]
16. [Lamivudine treatment consensus from relative experts].
Lamivudine Clinical Practice Group
Zhonghua Gan Zang Bing Za Zhi; 2002 Apr; 10(2):157-8. PubMed ID: 12108391
[No Abstract] [Full Text] [Related]
17. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients.
Chang TT; Gish RG; Hadziyannis SJ; Cianciara J; Rizzetto M; Schiff ER; Pastore G; Bacon BR; Poynard T; Joshi S; Klesczewski KS; Thiry A; Rose RE; Colonno RJ; Hindes RG;
Gastroenterology; 2005 Oct; 129(4):1198-209. PubMed ID: 16230074
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
Suzuki Y; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Miyakawa Y; Kumada H
J Gastroenterol Hepatol; 2009 Mar; 24(3):429-35. PubMed ID: 19226381
[TBL] [Abstract][Full Text] [Related]
19. Current treatment and future directions in the management of chronic hepatitis B viral infection.
Gish RG
Clin Liver Dis; 2005 Nov; 9(4):541-65, v. PubMed ID: 16207563
[TBL] [Abstract][Full Text] [Related]
20. [Prevention and treatment of hepatitis B virus reinfection after liver transplantation].
Liu J; Wu GC; Zhang ZT; Wu P; Zhang D; Sun MC; Gao DC; Wang Y; Jia JD; Wang BE
Zhonghua Wai Ke Za Zhi; 2005 Aug; 43(15):976-9. PubMed ID: 16194352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
